GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

Drugmaker GSK said it agreed to acquire Californian biopharmaceutical company RAPT Therapeutics RAPT 9.04%increase; green up pointing triangle for an estimated equity value of around $2.2 billion, a move set to bolster its respiratory, immunology and inflammation portfolio.

GSK said Tuesday that it made a deal to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash. The acquisition is expected to close in the first quarter of 2026 with an estimated aggregate equity value of $2.2 billion.